Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide and related compounds. A comparative study
- 1 August 1990
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 33 (8) , 2305-2309
- https://doi.org/10.1021/jm00170a040
Abstract
(S)-5-Bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide (6) and some related compounds, i.e. the R isomer 7, the 3-hydroxy analgoue 8, the desbromo derivative 9, the monomethoxy compound 10, and the 2,4-dimethoxy analgoue 11, have been synthesized from the corresponding benzoic acids. The benzamides, lacking o-hydroxy groups, were evaluated for their affinity for the [3H]spiperone binding site and for their inhibition of apomorphine-induced behavioral responses in relation to the effect of the corresponding salicylamides. Besides the 2-hydroxy-3-methoxybenzamide 12 and the related 1,4-benzodioxane (13) and 2,3-dihydrobenzofuran (14), carboxamides were investigated in order to evaluate the stereoelectronic requirements on the 2-methoxy group for the recepotr interaction. The study supports the view that the 0-methoxy group may adpot coplanar, as well as perpendicular orientations, and maintain the intramolecular hydrogen bonding required in the bioactive conformation. The benzamide 6 was found to be equipotent with the analogous highly active salicylamide 3 (FLB 463) both in vitro and in vivo. In addition, 6 displayed a preferential inhibition of the hyperactivity component of the behavioral syndrome which is regarded to indicate a low tendency to induce extrapyramidal side effects in man at antipsychotically effective doses. The benzamide class of compounds (6-10) were found to be somewhat more sensitive to the structural modifications than the salicylamide class, i.e. the o-hydroxy-substituted benzamides (2-5). The potent and selective benzamide 6 (FLB 457) is highly suitable for investigations of dopamine D-2 mediated responses and, in radiolabeled form, for receptor binding studies in vitro and in vivo.This publication has 14 references indexed in Scilit:
- An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PETPsychopharmacology, 1988
- Crystallographic, theoretical and molecular modelling studies on the conformations of the salicylamide, raclopride, a selective dopamine-D2 antagonistJournal of Pharmacy and Pharmacology, 1987
- NEW SELECTIVE DOPAMINE D-2 ANTAGONISTS AS ANTIPSYCHOTIC AGENTS - PHARMACOLOGICAL, CHEMICAL, STRUCTURAL AND THEORETICAL CONSIDERATIONS1987
- SOLID-STATE CONFORMATIONS AND ANTIDOPAMINERGIC EFFECTS OF REMOXIPRIDE HYDROCHLORIDE AND A CLOSELY RELATED SALICYLAMIDE, FLA 797, IN RELATION TO DOPAMINE RECEPTOR MODELS1986
- The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functionsPsychopharmacology, 1986
- Effects of Remoxipride and some Related New Substituted Salicylamides on Rat Brain ReceptorsActa Pharmacologica et Toxicologica, 1986
- Preparation of tritium labelled benzamide dopamine‐D2 lignads at high specific activityJournal of Labelled Compounds and Radiopharmaceuticals, 1985
- Some in vitro receptor binding properties of [3H]eticlopride, a novel substituted benzamide, selective for dopamine-D2 receptors in the rat brainEuropean Journal of Pharmacology, 1985
- Investigation on central dopaminergic receptors (D-2) using the antagonistic properties of new benzamidesJournal of Pharmacy and Pharmacology, 1984
- Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activitiesJournal of Medicinal Chemistry, 1982